Suzette Delaloge1,2, Martine Piccart3, Emiel Rutgers4, Saskia Litière5, Laura J van 't Veer6, Franchette van den Berkmortel7, Etienne Brain8, Aleksandra Dudek-Peric5, Miguel Gil-Gil9, Patricia Gomez10, Florentine S Hilbers11, Zaman Khalil12, Susan Knox13, Sherko Kuemmel14, Georg Kunz15, Anne Lesur16, Jean-Yves Pierga8,17, Peter Ravdin18, Isabel T Rubio19, Mahasti Saghatchian1, Tineke J Smilde20, Alastair M Thompson21, Giuseppe Viale22, Gabriele Zoppoli23, Peter Vuylsteke24, Konstantinos Tryfonidis5, Coralie Poncet5, Jan Bogaerts5, Fatima Cardoso25. 1. Gustave Roussy, Villejuif, France. 2. Unicancer Breast Group, Paris, France. 3. Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. 4. Netherlands Cancer Institute, Amsterdam, the Netherlands. 5. European Organization for Research and Treatment of Cancer, Brussels, Belgium. 6. Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA. 7. Zuyderland Medisch Centrum, Heerlen-Geleen, the Netherlands. 8. Institut Curie-Hôpital Rene Huguenin, Saint-Cloud, France. 9. Institut Catala D'Oncologia-Institut d'Investigacio Biomedica de Bellvitge, L'Hospitalet, Barcelona, Spain. 10. Hospital General Vall D'Hebron, Barcelona, Spain. 11. Breast International Group, Brussels, Belgium. 12. Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. 13. Europa Donna-The European Breast Cancer Coalition, Milan, Italy. 14. Breast Unit Kliniken Essen-Mitte, Westdeutsche Studiengruppe, Mönchengladbach, Germany. 15. St Johannes Hospital, Dortmund, Germany. 16. Institut de Cancérologie de Lorraine, Vandoeuvre-Les-Nancy, France. 17. Institut Curie Paris Sciences et Lettres, Université de Paris, Paris, France. 18. The University of Texas Health Sciences Center, San Antonio, TX. 19. Clinica Universidad de Navarra-Site Madrid, Madrid, Spain. 20. Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, the Netherlands. 21. Baylor University College of Medicine, Houston, TX. 22. University of Milan and European Institute of Oncology-Istituto di Ricovero e Cura a Carattere Scientifico, Milan, Italy. 23. University of Genoa and Azienda Ospedaliera Universitaria San Martino, Genova, Italy. 24. Centre Hospitalier Universitaire, Université Catholique de Louvain, Namur, Belgium. 25. Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal.
Abstract
PURPOSE: MINDACT demonstrated that 46% of patients with early breast cancer at high clinical but low genomic risk on the basis of MammaPrint may safely avoid adjuvant chemotherapy. A second random assignment (R-C) compared docetaxel-capecitabine with an anthracycline-based regimen. PATIENTS AND METHODS: R-C randomly assigned patients 1:1 between standard anthracycline-based regimens, with or without taxanes (control) and experimental docetaxel 75 mg/m2 intravenously plusoral capecitabine 825 mg/m2 two times per day for 14 days (DC) every 3 weeks for 6 cycles. The primary end point was disease-free survival (DFS). Secondary end points included overall survival and safety. RESULTS:Of 2,832 patients, 1,301 (45%) were randomly assigned, and 97% complied with R-C assignment. In the control arm, 29.6% only received taxanes (0.5% of N0 patients). DFS events (n = 148) were much less than required (n = 422) as a result of a lower-than-expected accrual and event rate. At 5 years of median follow-up, DFS was not different between DC (n = 652) and control (n = 649; 90.7% [95% CI, 88% to 92.8%] v 88.8% [95% CI, 85.9% to 91.1%]; hazard ratio [HR], 0.83 [95% CI, 0.60 to 1.15]; P = .26). Overall survival (HR, 0.91 [95% CI, 0.54 to 1.53]) and DFS in the clinical high and genomic high-risk subgroup (86.1% v 88.1%; HR, 0.83 [95% CI, 0.58 to 1.21]) were similar in both arms. DC led to more grade 1 neuropathy (27.1% v 11.2%) and more grade 2 hand/foot syndrome (28.5% v 3.3%) and diarrhea (13.7% v 5.8%). Serious cardiac events occurred in 9 patients (control, n = 4; DC, n = 5). Fifty-three patients developed second cancers (control, n = 32; DC, n = 21; leukemia: 2 v 1). Five treatment-related deaths occurred (control, 2 [0.3%]; DC, 3 [0.5%]). CONCLUSION: Although underpowered, this second randomization in MINDACT did not show any improvement in outcome or safety with the use of DC compared with anthracycline-based chemotherapy.
RCT Entities:
PURPOSE: MINDACT demonstrated that 46% of patients with early breast cancer at high clinical but low genomic risk on the basis of MammaPrint may safely avoid adjuvant chemotherapy. A second random assignment (R-C) compared docetaxel-capecitabine with an anthracycline-based regimen. PATIENTS AND METHODS: R-C randomly assigned patients 1:1 between standard anthracycline-based regimens, with or without taxanes (control) and experimental docetaxel 75 mg/m2 intravenously plus oral capecitabine 825 mg/m2 two times per day for 14 days (DC) every 3 weeks for 6 cycles. The primary end point was disease-free survival (DFS). Secondary end points included overall survival and safety. RESULTS: Of 2,832 patients, 1,301 (45%) were randomly assigned, and 97% complied with R-C assignment. In the control arm, 29.6% only received taxanes (0.5% of N0 patients). DFS events (n = 148) were much less than required (n = 422) as a result of a lower-than-expected accrual and event rate. At 5 years of median follow-up, DFS was not different between DC (n = 652) and control (n = 649; 90.7% [95% CI, 88% to 92.8%] v 88.8% [95% CI, 85.9% to 91.1%]; hazard ratio [HR], 0.83 [95% CI, 0.60 to 1.15]; P = .26). Overall survival (HR, 0.91 [95% CI, 0.54 to 1.53]) and DFS in the clinical high and genomic high-risk subgroup (86.1% v 88.1%; HR, 0.83 [95% CI, 0.58 to 1.21]) were similar in both arms. DC led to more grade 1 neuropathy (27.1% v 11.2%) and more grade 2 hand/foot syndrome (28.5% v 3.3%) and diarrhea (13.7% v 5.8%). Serious cardiac events occurred in 9 patients (control, n = 4; DC, n = 5). Fifty-three patients developed second cancers (control, n = 32; DC, n = 21; leukemia: 2 v 1). Five treatment-related deaths occurred (control, 2 [0.3%]; DC, 3 [0.5%]). CONCLUSION: Although underpowered, this second randomization in MINDACT did not show any improvement in outcome or safety with the use of DC compared with anthracycline-based chemotherapy.
Authors: Fatima Cardoso; Laura J van't Veer; Jan Bogaerts; Leen Slaets; Giuseppe Viale; Suzette Delaloge; Jean-Yves Pierga; Etienne Brain; Sylvain Causeret; Mauro DeLorenzi; Annuska M Glas; Vassilis Golfinopoulos; Theodora Goulioti; Susan Knox; Erika Matos; Bart Meulemans; Peter A Neijenhuis; Ulrike Nitz; Rodolfo Passalacqua; Peter Ravdin; Isabel T Rubio; Mahasti Saghatchian; Tineke J Smilde; Christos Sotiriou; Lisette Stork; Carolyn Straehle; Geraldine Thomas; Alastair M Thompson; Jacobus M van der Hoeven; Peter Vuylsteke; René Bernards; Konstantinos Tryfonidis; Emiel Rutgers; Martine Piccart Journal: N Engl J Med Date: 2016-08-25 Impact factor: 91.245
Authors: Joanne L Blum; Patrick J Flynn; Greg Yothers; Lina Asmar; Charles E Geyer; Samuel A Jacobs; Nicholas J Robert; Judith O Hopkins; Joyce A O'Shaughnessy; Chau T Dang; Henry Leonidas Gómez; Louis Fehrenbacher; Svetislava J Vukelja; Alan P Lyss; Devchand Paul; Adam M Brufsky; Jong-Hyeon Jeong; Linda H Colangelo; Sandra M Swain; Eleftherios P Mamounas; Stephen E Jones; Norman Wolmark Journal: J Clin Oncol Date: 2017-04-11 Impact factor: 44.544
Authors: Hyman B Muss; Donald A Berry; Constance T Cirrincione; Maria Theodoulou; Ann M Mauer; Alice B Kornblith; Ann H Partridge; Lynn G Dressler; Harvey J Cohen; Heather P Becker; Patricia A Kartcheske; Judith D Wheeler; Edith A Perez; Antonio C Wolff; Julie R Gralow; Harold J Burstein; Ahmad A Mahmood; Gustav Magrinat; Gutav Magrinat; Barbara A Parker; Ronald D Hart; Debjani Grenier; Larry Norton; Clifford A Hudis; Eric P Winer Journal: N Engl J Med Date: 2009-05-14 Impact factor: 91.245
Authors: Joseph A Sparano; Robert J Gray; Della F Makower; Kathleen I Pritchard; Kathy S Albain; Daniel F Hayes; Charles E Geyer; Elizabeth C Dees; Matthew P Goetz; John A Olson; Tracy Lively; Sunil S Badve; Thomas J Saphner; Lynne I Wagner; Timothy J Whelan; Matthew J Ellis; Soonmyung Paik; William C Wood; Peter M Ravdin; Maccon M Keane; Henry L Gomez Moreno; Pavan S Reddy; Timothy F Goggins; Ingrid A Mayer; Adam M Brufsky; Deborah L Toppmeyer; Virginia G Kaklamani; Jeffrey L Berenberg; Jeffrey Abrams; George W Sledge Journal: N Engl J Med Date: 2018-06-03 Impact factor: 91.245
Authors: V Möbus; G von Minckwitz; C Jackisch; H-J Lück; A Schneeweiss; H Tesch; D Elling; N Harbeck; B Conrad; T Fehm; J Huober; V Müller; I Bauerfeind; A du Bois; S Loibl; V Nekljudova; M Untch; C Thomssen Journal: Ann Oncol Date: 2017-08-01 Impact factor: 32.976
Authors: R Peto; C Davies; J Godwin; R Gray; H C Pan; M Clarke; D Cutter; S Darby; P McGale; C Taylor; Y C Wang; J Bergh; A Di Leo; K Albain; S Swain; M Piccart; K Pritchard Journal: Lancet Date: 2011-12-05 Impact factor: 79.321